MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
85.51
+0.94 (+1.11%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close84.57
Open84.97
Bid0.00 x 800
Ask0.00 x 2200
Day's Range84.74 - 86.03
52 Week Range59.80 - 86.50
Volume7,517,907
Avg. Volume10,246,128
Market Cap220.157B
Beta (3Y Monthly)0.29
PE Ratio (TTM)27.00
EPS (TTM)3.17
Earnings DateJul 30, 2019
Forward Dividend & Yield2.20 (2.60%)
Ex-Dividend Date2019-06-14
1y Target Est88.93
Trade prices are not sourced from all markets
  • Why These Innovative Biotech ETFs Soaring
    Zacks10 hours ago

    Why These Innovative Biotech ETFs Soaring

    Strong M&A activity has sent shares of many small, innovative biotech companies surging

  • Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?
    Zacks15 hours ago

    Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?

    Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).

  • Verastem Up on Positive Data From Early-Stage Copiktra Study
    Zacks18 hours ago

    Verastem Up on Positive Data From Early-Stage Copiktra Study

    Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

  • Dow on Pace for Best June: 5 Blue Chip Stocks to Buy
    Zacks18 hours ago

    Dow on Pace for Best June: 5 Blue Chip Stocks to Buy

    Dow eyes best June in 80 years as investors cheer the Fed's shift to a more dovish stance.

  • Benzinga3 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

    Biotech stocks came made upward moves last week after a rangebound period.  Among big pharma companies, Merck & Co., Inc. (NYSE: MRK ) was a standout gainer, notching up 52-week highs in successive sessions, ...

  • Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
    Zacks4 days ago

    Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

    Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

  • Dow Jones Today: A Typical Summer Friday
    InvestorPlace4 days ago

    Dow Jones Today: A Typical Summer Friday

    Interestingly, June 21 marks the official start of summer, and the summer months often bring lethargy in the equity markets, particularly on Fridays. That was the case today as stocks, broadly speaking, were mostly listless.Source: Shutterstock To close the week, the S&P 500 fell a scant 0.13%, and the Nasdaq Composite lost 0.24%. The Dow Jones Industrial Average also lost 0.13%. Long-term investors can find some solace on the day of the summer solstice with an article in Barron's today indicating Dow 30,000 could arrive sooner than expected."To stick with our 2025 forecast now would be to suggest that stocks over the next 5½ years will climb just 2.1% a year, plus dividends," according to Barron's. "It's possible, but pessimistic. The Dow could reach 30,000 much sooner than 2025."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe article indicates it is possible the Dow sees 30,000 sometime in 2021, a bullish forecast considering the blue-chip index closed around 26,800 today.That is a long-term forecast. Over the near-term, the Federal Reserve will likely dominate the conversation and that is not surprising. For investors hoping for rate cut this year, good news: Fed funds traders bet on such a move in record fashion this week, according to CNBC. Some Mild WinnersBy the end of the day, just two of the 30 Dow Jones stocks were sporting gains of 1% or more. The clear powerhouse was UnitedHealth Group (NYSE:UNH), which gained 1.82% on new that it is acquiring health-care payments provider Equian LLC for $3.2 billion. * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 That is a drop in the bucket for UnitedHealth, which has a market capitalization of $240 billion and a stellar return for Equian's private equity owner New Mountain, which purchased the company four years ago for just $225 million.Defensive names have been getting some attention here in recent weeks and with good reason. Today, Dow component Walmart (NYSE:WMT), on essentially no news to merit a move like this, jump 0.73% to hit an all-time high. The largest U.S. retailer is up almost 20% year-to-date.Pharmaceuticals giant Pfizer (NYSE:PFE) added 0.88% after the European Commission approved the company's TALZENNA treatment for breast cancer patients. The U.S. Food and Drug Administration (FDA) approved the treatment last October."We are thrilled that we can now offer these patients in Europe, who are often diagnosed at a younger age and have limited treatment options, an effective, once-daily, alternative treatment to chemotherapy," said Pfizer in a statement.Staying in the blue-chip pharmaceuticals space, Merck & Co. (NYSE:MRK) closed modestly lower, but three analysts raised price targets on the stock to $90, $95 and $96, respectively. In either case, that is some decent upside from Merck's Friday close around $84.50. Bottom Line on the Dow Jones TodayWith all the talk about a potential rate cut, investors should not forget that second-quarter earnings season will soon be here. While glum earnings may be baked into the market at current levels, investors should still expect some less-than-positive sentiment around the second-quarter numbers."As of today, the estimated earnings decline for the second quarter for the S&P 500 stands at -2.6%," said FactSet in a note out Friday. "If -2.6% is the actual earnings decline for the quarter, it will mark the first time the index has reported two straight quarters of year-over-year declines in earnings since Q1 2016 and Q2 2016. It will also mark the largest year-over-year decline in earnings since Q2 2016 (-3.2%)."Unfortunately, the same note indicates analysts are ratcheting down third-quarter estimates with the energy and technology sectors looking like the worst offenders.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 * 5 Boring Stocks to Buy This Summer * 7 S&P 500 Stocks to Buy With Little Debt and Lots of Profits Compare Brokers The post Dow Jones Today: A Typical Summer Friday appeared first on InvestorPlace.

  • Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
    Zacks4 days ago

    Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

    Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

  • Barrons.com4 days ago

    Merck Signals Stability at Rare Investor Day. Wall Street Wants More Information.

    The pharmaceutical company has benefited from sales of Keytruda, a cancer drug, but investors want to know what is next.

  • Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
    Zacks4 days ago

    Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

    The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.

  • Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
    Zacks4 days ago

    Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

  • Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
    Zacks4 days ago

    Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

    Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

  • Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries
    Reuters5 days ago

    Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

    Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted. U.S. President Donald Trump said last year that one way his administration would seek to lower drug costs to consumers could be through an international pricing index (IPI) that would determine what Medicare pays for certain medicines based on the prices set in a handful of other countries. "I think there will be challenges to the rule," Frazier told reporters following the drugmaker's investor day in New York.

  • Should You Be Adding Merck (NYSE:MRK) To Your Watchlist Today?
    Simply Wall St.5 days ago

    Should You Be Adding Merck (NYSE:MRK) To Your Watchlist Today?

    It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

  • Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice
    Zacks5 days ago

    Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice

    Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Stock Market News For Jun 20, 2019
    Zacks5 days ago

    Stock Market News For Jun 20, 2019

    Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.

  • AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
    Zacks5 days ago

    AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod

    AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.

  • TheStreet.com5 days ago

    Here's Why I'm Sticking With Merck

    About six months ago, I declared Merck & Co. The pharmaceutical sector has had its ups and downs this year, partly due to promises by President Trump and some members of Congress to fight for lower drug prices. Given this underperformance, are we sticking with Merck as our top choice for the year?

  • Benzinga5 days ago

    The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 19) Abbott Laboratories (NYSE: ABT ) CareDx Inc (NASDAQ: ...

  • Business Wire5 days ago

    Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development

    At a meeting with the investment community today, Merck (MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term. “Merck is very well positioned to pursue its mission to save and improve lives,” said Kenneth C. Frazier, Merck chairman and chief executive officer.

  • Pfizer Stock Is The Biggest Pharma — But Should You Buy It?
    Investor's Business Daily6 days ago

    Pfizer Stock Is The Biggest Pharma — But Should You Buy It?

    Pfizer stock has fallen 2% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?

  • Merck's Keytruda Gets 2nd Label Expansion Approval in June
    Zacks6 days ago

    Merck's Keytruda Gets 2nd Label Expansion Approval in June

    Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.

  • Benzinga6 days ago

    The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals ...

  • Merck (MRK) Outpaces Stock Market Gains: What You Should Know
    Zacks7 days ago

    Merck (MRK) Outpaces Stock Market Gains: What You Should Know

    Merck (MRK) closed at $84.45 in the latest trading session, marking a +1.38% move from the prior day.